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We have examined the tissue-speciﬁc mRNA expression of ERa and ERb in various bovine tissues
using real-time RT-PCR. The goal of this study was to evaluate the deviating tissue sensitivities and
the inﬂuence of the estrogenic active preparation RALGRO on the tissue-speciﬁc expression and
regulation of both ER subtypes. RALGRO contains Zeranol (a-Zearalanol), a derivative of the myco-
toxin Zearalenon, shows strong estrogenic and anabolic effects, and exhibits all symptoms of hyperes-
trogenism, in particular reproductive and developmental disorders. Eight heifers were treated over 8
weeks with multiple-dose implantations (0À,1 À,3 À,1 0 À) of Zeranol. Plasma Zeranol concentration,
measured by enzyme immunoassay, of multiple treated heifers was elevated. To quantify ERa and
ERb transcripts also in low-abundant tissues, sensitive and reliable real-time RT-PCR quantiﬁcation
methods were developed and validated on the LightCycler. Expression results indicate the existence
of both ER subtypes in all 15 investigated tissues. All tissues exhibited a speciﬁc ERa and ERb
expression pattern and regulation. With increasing Zeranol concentrations, a signiﬁcant downregula-
tion of ERa mRNA expression could be observed in jejunum (p,0.001) and kidney medulla (p,0.05).
These data support the hypothesis that ERb may have different biological functions than ERa, espe-
cially in kidney and jejunum.
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CloningandsequencingofERbinhuman(1),rat
(2), and mouse (3) has provided the ﬁrst example
ofasteroidhormonereceptorexistingintwoiso-
forms, each of which is encoded by a separate
gene. The ERb protein is smaller than the pre-
viously identiﬁed ERa (4, 5), but possesses the
modularstructureofdistinctfunctionaldomains
(A-F) characteristic of members of the nuclear
receptors. The DNA-binding domain of ERa
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and ERb is highly conserved over several species
(.95% homology in Homo sapiens, Rattus
norwegicus, Mus musculus, Bos taurus) and the
ligand-binding domain shows ¶60% conserved
residues(6–8).ERbseemstobeanimportantad-
ditional factor in the mechanism of estrogen ac-
tion and has an overlapping but nonidentical
tissue distribution in comparison to ERa.I ti s
expressed in humans and rodents in the central
nervous system, the cardiovascular system, the
immune system, and in the gastrointestinal tract
(9–11). Within the same organ it often appearsPFAFFL et al.
that the ER subtypes are expressed differentially,
supporting the hypothesis that both receptors
may have different biological functions. Ligand-
binding experiments have shown speciﬁc binding
of estradiol-17b and transactivation of ERb with
an afﬁnity similar to ERa (12). But the mechan-
ism of activation by endogen steroids, phytoetro-
gens, xenosteroids and related synthetic drugs
was shown to be highly complex (6, 13, 14).
Knowledge of the distribution and regulation of
ERb in various tissues of ruminants is lacking at
present. The available publications about ERb
expression in bovids are limited to cattle repro-
ductive organs (8, 15) and the sheep hypothala-
mus (16, 17). However, a more detailed study of
the tissue distribution of both ER subtypes is es-
sential to continuing investigations of their regu-
lation and physiological function. It is well
known that steroids lead to an increased syn-
thesis of speciﬁc proteins (18) and it is proposed
that estradiol can stimulate via ERa its own re-
ceptor expression at least in the uterus (19). The
goal of this study was to evaluate the deviating
tissue sensitivities and the inﬂuence of the estro-
gen-active preparation RALGROA (Mallinck-
rodt Veterinary, Inc., Mundelein, IL, USA) on
the tissue-speciﬁc expression pattern and regula-
tion of both ER subtypes. One RALGRO im-
plant contains 36 mg a-Zearalanol (Zeranol), a
derivative of the mycotoxin Zearalenon, and
shows strong estrogenic and anabolic effects in
farm animals. Besides this, it exhibits all the
symptoms of hyperestrogenism, in particular re-
productive and developmental disorders. Herein
we describe a reverse transcription followed by a
real-time polymerase chain reaction (RT-PCR)
using the LightCycler system (Roche, Basel, Su-
isse) to detect and quantify these mRNA tran-
scripts from both genes. For low abundancies,
sensitive and reliable real-time RT-PCR quanti-
ﬁcation methods were developed and validated.
RT-PCR real-time assays with an external cali-
bration curve are quantitative and therefore an
absolute comparison of ERa and ERb within
one tissue RNA preparation will be possible.
MATERIAL AND METHODS
Animal experiment and sampling
Six Holstein Friesian heifers were treated with the
implant preparation RALGROA (1À½36 mg Zeran-
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ol) 8 weeks before slaughter. Two animals served as
control, two were given single, two 3-fold and two 10-
fold doses of the preparation. Blood samples were
taken on day 0, 1, 8, 22, 36, 49 and 56 of the treat-
ment period. During sampling, an anticoagulative
agent (6 mM EDTA and 0.02% acetylsalicylic acid
ﬁnal) was added. Plasma was prepared by centrifuga-
tion and decantation. Aliquots were stored at »20¾C
until processing.
Gynaecological inspection of animals after slaughter
During dissection of the inner organs the genital
tract of the heifers was removed completely and pre-
pared for morphological inspection. The inspection
comprised the following: 1) An estimation of the oes-
trus cycle day, according to the criteria of Ireland et
al. (20); 2) Uterus condition (size, existence and ap-
pearance of mucus); 3) Corpus luteum (existence of
possible cysts, post- or preovulatory status and any
unphysilogical appearance); 4) Number of follicles,
divided into large dominant (.10 mm in diameter)
or small (3–10 mm). The corpus luteum and follicle
data represent the gynaecological results from both
ovaries.
Detection of Zeranol in plasma
The plasma contents of Zeranol were analysed by
enzyme immunoassay (EIA) after liquid-liquid ex-
traction. 0.5 ml plasma was thoroughly shaken over-
night with 2 ml tertiary-butyl methyl ether (TBME)/
petroleum ether 70/30 (v/v). After separation of the
organic and the plasma phase the samples were deep
frozen at »60¾C for 30 min. The supernatant was
decanted and evaporated to dryness in a shaking
water bath at 60–80¾C. The residue was re-dissolved
in 0.25 ml 40% methanol and 20 mL of this extract
was analysed in duplicate by a speciﬁc enzyme
immunoassay (rabbit antiserum 1:1,400,000, antigen:
zeranol-16-carboxy-propylether-BSA; 2.9 ng zeranol-
16-carboxybutyl ether-horseradish peroxidase per
well). The working interval ranged from 10 pg/ml
(85% displacement of labelled antigen) to 1740 pg/
ml plasma (15% displacement of labelled antigen). To
validate the detection method, aliquots of a pool of
negative plasma samples were fortiﬁed with 0 pg, 100
pg, 200 pg or 400 pg Zeranol/ml and analysed ac-
cording to the standard protocol. The EIA assay
showed a mean recovery of 106%, an intra-assay vari-
ation of 3.1%, an inter-assay variation of 11%, a limit
of detection of 12 pg/ml, and a cross-reaction with
other Zeranol metabolites and steroid hormones of
maximal 6.5% (21).
Total RNA extraction
0.5 g frozen tissue was homogenised in 4 M guani-
dinium thiocyanate buffer to destroy RNase activity
(22). In the following steps, the RNA-Clean protocol
(AGS RNA-Clean; AGS, Heidelberg, Germany) with
phenol/chloroform extraction for total RNA wasERa AND ERb EXPRESSION PATTERN
used. In order to quantify the amount of total RNA
extracted, the optical density was determined with an
Ultraspec 3000 photometer (Pharmacia) at three dif-
ferent dilutions of the ﬁnal RNA preparations at 260
nm, corrected by the 320 nm background absorption.
RNA integrity was electrophoretically veriﬁed by
ethidium bromide staining and by OD260/OD280 nm
absorption ratio .1.85.
ERa and ERb speciﬁc primer design
The primers of both subtypes were derived from
the bovine and ovine sequences [EMBL Ac. no.
AF110402; Y18017; Z49257; AF177936]. Both
primer pairs were designed to produce a ERa (234
bp) and ERb (262 bp) ampliﬁcation product span-
ning two RNA-splicing sites in the region of the re-
ceptor ligand-binding domain, where only ¶60%
homology is given. Primer design and optimisation
was done with the Mac DNASIS primer design soft-
ware (Hitachi Software, Yokohama, Japan). Primer
sequences were additionally designed as multi-species
primers (ERa forward primer: 5¿-AGG GAA GCT
CCT ATT TGC TCC -3¿;E R a reverse primer: 5¿-
CGG TGG ATG TGG TCC TTC TCT-3¿;E R b for-
ward primer: 5¿-GCT TCG TGG AGC TCA GCC
TG-3¿;E R b reverse primer: 5¿-AGG ATC ATG
GCC TTG ACA CAG A-3¿; produced by MWG Bi-
otech, Ebersberg, Germany), which ﬁt to the follow-
ing species with high precision (.90%): cattle (Bos
taurus), sheep (Ovis aries), human (Homo sapiens),
pig (Sus scrofa), mouse (Mus musculus) and rat
(Rattus norwegicus).
Reverse transcription (RT)
1 mg total RNA from sample preparation was re-
verse transcribed in 40 ml as followed: M-MLV RT
buffer (Promega, Mannheim, Germany) and 300 mM
dNTPs (MBI Fermentas) were denaturated for 5 min
at 65¾C in an Mastercycler Gradient (Eppendorf,
Germany). The subsequent RT was done at 37¾C for
60 min by adding 2.5 mM Random Hexamer primers
(Pharmacia), 200 U of M-MLV Reverse Trancriptase
(Promega), 12.5 U of RNAsin RNase inhibitor (MBI
Fermentas). The samples were then heated for 1 min
at 99¾C to terminate RT.
Optimisation of ER subtype-speciﬁc RT-PCR
Conditions for RT-PCRs were optimised in a gradi-
ent cycler with regard to Taq DNA Polymerase (Ro-
che), PCR water, pH, primers (MWG), MgCl2 (Ro-
che) concentrations and various annealing tempera-
tures. Ampliﬁcation products were separated on by
4% high resolution NuSieve agarose (FMC Bio Prod-
ucts) gel electrophoresis and analysed with the Image
Master system (Pharmacia). Optimised results were
transferred according to the following LightCycler
PCR protocol.
LightCycler PCR master mix
For the LightCycler reactions a master mix of the
following reaction components was prepared to the
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indicated end concentration: 6.4 ml water, 1.2 ml
MgCl2 (4 mM), 0.2 ml Forward Primer (0.4 mM), 0.2
ml Reverse Primer (0.4 mM) and 1.0 ml LightCycler
DNA Master SYBR Green I (1À). 9 mlo f
LightCycler master mix was ﬁlled in the LightCycler
glass capillaries and 25 ng reverse transcribed total
RNA in 1 ml was added as PCR template. The capil-
laries were closed, centrifuged in a microcentrifuge,
and placed in the LightCycler rotor (Roche).
LightCycler PCR time and temperature proﬁles
A conventional LightCycler ampliﬁcation cycle
contains three segments: In the 1st segment DNA is
denaturated at 95¾C. In the 2nd annealing segment
the primer annealing takes place and the chosen tem-
perature should be as high as possible to improve
speciﬁcity. Within the following 3rd elongation seg-
ment at 72¾C, the elongation time should be adapted
to the length of the desired product, which is limited
by Taq Polymerase processing rate (¶1000 bp/min
elongation time). To improve SYBR Green IA quanti-
ﬁcation a new 4th segment with a high temperature
ﬂuorescence acquisition point was included in the
ampliﬁcation cycle program. The following
LightCycler protocol was used for ERa and ERb
real-time PCR: denaturation program [95¾C for 30 s],
a 4 segment ampliﬁcation and quantiﬁcation program
repeated 50 times for ERa [95¾Cf o r3s ;6 4¾C for 10
s; 72¾C for 20 s; 82¾C for 3 s with a single ﬂuor-
escence acquisition point], and for ERb [95¾C for 3
s; 64¾C for 10 s; 72¾C for 20 s; 87¾C for 3 s with a
single ﬂuorescence acquisition point], melting curve
program [60¾Ct o9 5¾C with a heating rate of 0.1¾C/
s and a continuous ﬂuorescence acquisition] and a
ﬁnal cooling program down to 40¾C. The display
mode and the ﬂuorimeter gains of channel 1 were set
to 5.
Calibration curves
For both quantitative assays, an external cali-
bration curve was used, based on a single-stranded
DNA (ssDNA) molecule calculation. ERa and ERb
RT-PCR products from Bos taurus were cloned separ-
ately in pCR4.0 (Invitrogen, Leek, The Netherlands),
linearised by a unique restriction digest, and dilutions
of each plasmid preparation from single copies of
ssDNA up to 1010 ssDNA molecules were used in
calibration curves.
RESULTS
Gynaecological status of treated heifers after
section
The gynaecological status of both untreated
control animals dated on day 14 to 16 of the
oestrus cycle showed physiological uterus and
ovary conditions. Heifers treated with 1-foldPFAFFL et al.
Zeranol were in day 18–20 of the oestrus cycle
and the uterus showed a normal constitution
with cervical mucus. On the ovaries both ani-
mals had one dominant and up to 10 small fol-
licles. Besides this, one of them showed a corpus
luteum. Heifers treated with multiple implan-
tation (3À and 10À) had a very small uterus,
cervical mucus, and the number of follicles was
limited to 6.
Zeranol concentrations in plasma
The Zeranol concentrations measured in
plasma of control animals were constant at a
level of 6.9º1.9 pg/ml plasma (n½14). In
treated animals, the plasma levels were elevated
(Fig. 1) over the ﬁrst half of the treatment
period, corresponding to the multiple Zeranol
treatment concentrations. At slaughter on day
56, the plasma concentrations dropped to
values below 30 pg/ml, but were elevated in
comparison to background concentrations.
Conﬁrmation of primer speciﬁcity and sequence
analysis
For exact length veriﬁcation, RT-PCR prod-
ucts were separated by 4% high resolution gel
electrophoresis. Ampliﬁed gradient Mas-
terCycler and LightCycler PCR products
showed a single band and the expected length
Fig. 1. Zeranol concentrations in plasma from six
heifers treated with multiple dose of the estrogen-ac-
tive preparation RALGROA (1À,3 À and 10À) dur-
ing 56 d treatment period. Mean Zeranol back-
ground (6.9 pg/ml; n½14) was measured in both con-
trol animals.
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of 234 bp for ERa and 262 bp for ERb (Fig. 2).
Speciﬁcity of the desired products was addition-
ally documented with melting curve analysis of
LightCycler Software 3.39 (Roche). Melting
temperature of the high speciﬁc products is spe-
cies and receptor subtype dependent (Table 1)
between 85.0¾C to 86.0¾C for ERa and 88.8¾C
to 89.3¾C for ERb. Sequence analysis (MWG
Biotech, Ebersberg, Germany) of cloned RT-
PCR products from Bos taurus showed 100%
homology to the published sequences.
Real-time RT-PCR assay validation
Both real-time RT-PCR were ERa and ERb
product speciﬁc, and effective PCR ampliﬁ-
cation kinetics was shown by high PCR ef-
ﬁciency per cycle (Table 1). Assay sensitivities
were conﬁrmed by detection limits down to 10
ssDNA molecules and linear quantiﬁcation
ranges between 102 to 109 molecules. Intra- and
inter-assay variations of ,19% to ,30%, re-
spectively, were determined over the entire
quantiﬁcation range. The advantage of a high
temperature ﬂuorescence acquisition in the 4th
segment during the ampliﬁcation program re-
sults in reliable and sensitive ER subtype-speci-
ﬁc quantiﬁcation with high linearity (Pearson
correlation coefﬁcient; r.0.995) over seven or-
ders of magnitude. High temperature ﬂuor-
escence acquisition melts the unspeciﬁc PCR
products at 82¾C and 87¾C, respectively, elimin-
ates the non-speciﬁc ﬂuorescence signal derived
from primer dimers, and ensures an accurate
quantiﬁcation of the desired products (Fig. 2).
Tissue-speciﬁc ERa and ERb mRNA expression
ERa and ERb mRNA expression could be
observed in all 15 investigated tissues. Table 2
summarizes the mean mRNA expression rates
of the ER subtypes and their ERa/ERb ratio
for all eight investigated animals with variation
coefﬁcient (VQ). Expression data were pooled,
because in most tissues (13 of 15) no effect of
Zeranol treatment on the ER expression proﬁles
could be detected. The classical tissues for estro-
gen action such as uterus, udder and liver
showed high ERa expression. High ERa expres-
sion could also be observed in muscles such as
neck muscles . hind leg muscles . longissimus
dorsi . shoulder muscles. High ERb was ob-
served in uterus . kidney . and spleen . long-
issumus dorsi . udder . liver. In comparisonERa AND ERb EXPRESSION PATTERN
Fig. 2. LightCycler 234 bp ERa (C) and 262
bp ERb (E) RT-PCR products in comparison
with the 100 bp ladder (A) and the no tem-
plate controls (B and D).
to ERa and ERb, the expression rates (on a
moleculer basis per 25 ng) were lower in most
tissues, except in kidney and jejunum, where the
ERa/ERb ratios were ,1. High ERa/ERb ra-
tios were examined in some muscle parts, liver,
udder and uterus. To make the individual tissue
expression pattern evident, all mean ERa and
ERb expression rates were shown (Fig. 3) in
molecules per 25 ng total RNA with bidirec-
tional error bars (meanºs.e.m.). Each tissue
possesses an ERa and ERb expression pattern
which stays relatively stable even during Zeran-
TABLE 1. Characteristics and validation parameters of multispecies ERa and ERb real-time RT-PCR in the
LightCycler system. PCR product-speciﬁc melting temperature (Tmelt in ¾C) of ERa and ERb of the investigated
species
ERa ERb
Product length 234 bp 262 bp
Detection limit 2 molecules 10 molecules
Quantiﬁcation limit 165 molecules 106 molecules
Quantiﬁcation range (test linearity) 165–1.65À109 molecules 106–1.06À1010 molecules
(r½0.995) (r½0.996)
PCR efﬁciency 1.812 1.813
Intra-assay variation 18.7% (n½4) 17.6% (n½4)
Inter-assay variation 28.6% (n½4) 29.7% (n½4)
Investigated species and speciﬁc Tmelt (¾C) Rattus norvegicus 85.0 Bos taurus 89.3
Bos taurus 85.3 Ovis aries 88.8
Ovis aries 85.4
Sus scrofa 86.0
Homo sapiens 86.0
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ol treatment and resulted in an ERa/ERb ex-
pression cluster (Fig. 3). Highest expression
rates of ER subtypes were observed in uterus
and low concentrations in tissues of the gastro-
intestinal tract. A signiﬁcant relationship be-
tween increasing estrogen concentrations and
decreasing ERa expression was observed in kid-
ney medulla (p,0.001) and jejunum (p,0.05)
(Fig. 4), not in uterus. Liver, jejunum, abo-
masum, mammary gland, spleen, lung, kidney
cortex and longissimus dorsi showed only a
trend to decreased expression. In the remainingPFAFFL et al.
TABLE 2. Expression pattern of ERa and ERb mRNA and expression ratio (ERa/ERb) in 25 ng bovine total
RNA. Mean expression (in mRNA molecules) and variation coefﬁcient (VQ) of eight animals
ERa VQ ERb VQ Ratio
ERa/b
Uterus 980,000 53% 80,000 140% 12
Mammary gland 205,000 105% 7,250 64% 28
Liver 200,000 87% 6,250 179% 32
Lung 5,400 167% 900 94% 6
Spleen 12,000 65% 10,400 104% 1.2
Heart muscle 6,000 82% 4,200 56% 1.4
Kidney medulla 10,200 52% 35,100 65% 0.3
Kidney cortex 4,200 57% 29,300 51% 0.14
Rumen 4,060 53% 1,350 109% 3
Abomasum 4,600 84% 650 157% 7
Jejunum 1,550 72% 2,150 152% 0.7
Longissimus dorsi 79,400 61% 8,650 22% 9
Hind leg muscles 100,000 47% 5,850 76% 17
Shoulder muscles 60,500 83% 2,600 93% 23
Neck muscles 145,000 79% 2,250 133% 64
Fig. 3. Tissue-speciﬁc ERa and ERb mRNA expression cluster from 15 tissues. Transcripts were measured on
a moleculer basis with real-time RT-PCR in 25 ng total RNA (n½8) and quantiﬁed results are shown as mean
with bidirectional error bars (s.e.m.).
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Fig. 4. Relation between multiple treatment with estrogen-active preparation RALGROA (1À½36 mg Zeranol)
and ERa expression in 25 ng total RNA in kidney medulla (p,0.05) and jejunum (p,0.001) in heifers (n½8).
tissues no trends towards change in either ERa
or ERb expression levels could be detected.
DISCUSSION
The cloning of ERb has introduced a new level
of complexity of estrogen action. Since it was
discovered, no deﬁnite statement regarding its
expression pattern in various tissues and its
unique function has been made. This paper fo-
cuses on the tissue distribution and expression
pattern of both subtypes (ERa and ERb)i n
major tissues and under estrogenic active RAL-
GRO treatment in Bos taurus.
a-Zearalanol (Zeranol) possesses estrogenic
potencies that are approximately 50–60% com-
pared to that of estradiol-17b. Estrogenicity was
evaluated using either a competitive receptor
binding assay in ﬁsh models (23) or an enzyme-
linked receptor assay (24). Therefore, the 1-fold
RALGRO dosage represents approximately a
physiological estrogen concentration in com-
parison to estradiol-17b occurring at cattle oes-
trus. After application of a simple RALGRO
dose the oestrus cycle is obviously arrested at
the preovulatory stage. The multiple dosage re-
sulted in an inﬂuence on or even a possible
blockage of the oestrus cycle, accompanied by
distinctively small uterus sizes, as described
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earlier (25). Estradiol-17b directly regulates the
gondotropin-releasing hormone (GnRH) ex-
pression at the level of GnRH neurons and may
exert its neuroendocrine control through direct
interaction with speciﬁc receptors expressed in
these cells (26). This clearly indicates the nega-
tive feedback mechanism on the gonadotropic
axis caused by the high estrogen concentrations.
Plasma Zeranol measurement by EIA was a
sensitive and reliable quantiﬁcation method-
ology. Concentrations in RALGRO-treated ani-
mals resulted in measurable and elevated Zeran-
ol levels in comparison to the control group,
whereas a quantiﬁcation with radioimmunoas-
say (RIA) did not give different results between
the 36 mg Zeranol-treated and untreated groups
(27). The decrease in Zeranol levels in plasma
in the 10-fold group after day 35 might be due
to a reduced drug absorption from the im-
plants, which were degraded during this period.
To detect ERa and ERb mRNA transcripts a
real-time RT-PCR quantiﬁcation on a
LightCycler was used. RT followed by real-time
PCR is a sensitive method to quantify low
amounts of mRNA molecules (28, 29) and of-
fers important insights into the local expression
and para- and autokrine regulation. The re-
liability of such an assay depends on the sensi-
tivity, the inter-test variations, and on a sufﬁ-
ciently wide linear quantiﬁcation range. In thisPFAFFL et al.
paper we describe the design and validation of
a real-time RT-PCR according to the demands
of a fast-cycle PCR (30). RT-PCR real-time as-
says with an external calibration curve are di-
rectly quantitative and therefore an absolute
comparison of ERa and ERb mRNA molecules
is possible. As demonstrated herein, ERa and
ERb LightCycler RT-PCR meets these test par-
ameter requirements with excellent perform-
ance. We have used this ER subtype-speciﬁc
mRNA quantiﬁcation system to determine the
expression levels, the tissue distribution, and to
compare the tissue-speciﬁc expression pattern
of both ER subtypes in Bos taurus. Methods
such as multispecies quantiﬁcation tests were
developed and can be used in other species such
as humans, sheep, pig and rat with sufﬁciently
high homologies of the primer recognition sites.
ERb was previously detected in a few species
and tissues (9, 11, 13, 31), but a direct compari-
son and quantiﬁcation of both ER subtype
mRNA within one tissue is not available so far.
A comparison and co-expression of ERa and
ERb study had already been done in normal
mice and ERa knockout mice (ERKO mice) by
ribonuclease protection assay (RPA) (32). RPA
with following densitometric analysis of band
intensities is a comparative, not a quantitative
methodology. The assay detected the relative
ERa and ERb mRNA expressions in various
organs of the female and male reproductive
tracts. In further publications, ERa and ERb
expression and regulation in rat ovary was in-
vestigated by Northern Blotting and RT-PCR
(33, 34). Quantiﬁcation of the ER-speciﬁc sub-
types was done semiquantitatively via RT-PCR
with the following densitometric analysis of
ethidium bromide-stained gels. In uterus, ERa
was the major transcript, whereas in ovary
granulosa cells, the ERb transcript is dominant.
ERa/ERb expression ratio (R) was determined
to be in the range 0.5 to 1.0 over the rat ovarian
cycle with very close ERa/ERb ratios. From
our own studies in bovine ovarian tissues (data
not published) we can conﬁrm the expression of
both subtypes and the dominant ERb expres-
sion in granulosa cells (R½0.10) and theca cells
(R½0.85). ERb is functional in granulosa cells,
regulated by ovulatory doses of gonadotropins,
and seems to be a modulator of ERa action
during follicular development (34). In contrast,
in bovine corpus luteum, ERa is the dominant
352
estrogen receptor subtype with a wide expres-
sion ratio (R½16.7; data not published).
As presented herein, we detected and quan-
tiﬁed ERa and ERb transcripts in all 15 investi-
gated tissues. The results of the multiple im-
plantation of the estrogen-active compound
showed a dose-dependent downregulation of
ERa expression only in kidney medulla and je-
junum. The remaining tissues were not signiﬁ-
cantly inﬂuenced by estrogen treatment, only
trends towards a down- or upregulation were
observed with high variations. The hypothesis
that estrogens (19) can stimulate ERa expres-
sion via its own receptor could not be conﬁrmed
in this study. The opposite hypothesis must even
be reached that excessive Zeranol will down-
regulate the ERa expression in kidney medulla
and jejunum. Estradiol-17b-treated mice
showed increased uterus size, but decreased
ERb expression (35). The authors conclude that
ERb plays an important role in modulation of
the effects of ERa and, in addition, or as a
consequence of this, has a regulatory function
in the uterus. In isolated rat granulosa cells, a
signiﬁcant downregulation of ERa under estro-
gen-active DES (diethylstilboestrol) treatment
could be shown (36). However neither Zeranol
nor DES will act like the physiological ligand
estradiol-17b.
As a result of the mainly nonsigniﬁcant re-
lationship (except in kidney-medulla and je-
junum) between Zeranol treatment and ERa
and ERb expression levels, all expression data
within one tissue were pooled. The derived
mean expression concentrations and variations
are characteristic for all investigated tissues and
the relation between the two ER subtypes re-
sults in a tissue-speciﬁc expression cluster. More
detailed studies of this ERa/ERb cluster with its
tissue-speciﬁc variations will lead us to a better
understanding of receptor regulation and physi-
ology. Data show high ERa expression rates in
the classical estrogen-sensitive tissues and a
wide ERa/ERb ratio. ERb transcripts were
mainly expressed at a lower level. The dominant
ERa expression (R½2.6) could also be shown in
various brain regions, including hypothalamus,
pituitary gland and six different brain lobes
(data not published). No expression of ERa
could be observed in the bovine endothelial cell
preparation, whereas the ERb transcripts
showed very low-abundant expression (data notERa AND ERb EXPRESSION PATTERN
published). The dominant role of ERa, espe-
cially in uterus, explains why it was the ﬁrst
cloned ER as most puriﬁcation and cloning and
attempts were based on uterine tissue (7).
Both subtypes could also be detected in the
muscular tissues with a very wide expression
ratio, especially in muscle parts which are in-
volved in cattle allometric growth such as neck
and shoulder muscularity. The molecular basis
for this sexually dimorphic muscle growth pat-
tern might be attributed to relatively higher sen-
sitivities to sexual steroids in these muscles (37).
Over and above that, the present study implies
that local differences in ERa expression might
be one promoting factor for higher growth velo-
cities and might play a key role in allometric
growth.
The localisation and dominant expression of
ERb in both kidney regions and in the jejunum
leads to the hypothesis that ERb plays a domi-
nant role in these tissues. ERa had already been
detected in the bovine gastrointestinal tract (38),
but ERb might play the major role in the ab-
sorptive processes. However, whilst any notions
as to the direct physiological effects of estrogens
on gastrointestinal tissues and kidney remain
speculative, there are some indications that es-
trogens might inﬂuence the calcium transport in
rats (39).
CONCLUSION
In view of the data provided for sensitivity, lin-
earity and reproducibility, the RT-PCR assay
developed here allows the absolute and accurate
quantiﬁcation of ERa and ERb mRNA mol-
ecules with a sufﬁciently high sensitivity even
for tissues with low abundancies down to a few
molecules. Our expression results indicate the
existence of two ER subtypes in various bovine
tissues, their different expression pattern and
co-expression, as well as their tissue-speciﬁc
regulation during estrogen treatment. These dif-
ferent expression patterns of ERa and ERb can
be regarded as supporting the hypothesis that
ER subtype proteins may have different biologi-
cal functions, especially in kidney and jejunum
where there is an inverse ERb expression ratio
in comparison to the other investigated tissues.
In the future more detailed studies of ERa and
ERb must be carried out in all kidney cell types
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and all parts of the gastrointestinal system as
part of continuing investigations into ER regu-
lation and its physiological function.
Animal experiments and RALGRO treatment were
carried out in collaboration with EU project B6–
7920/98/000008.
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